

# 2Q 2024 Earnings Conference Call

August 1, 2024

## Safe Harbor Regarding Forward-Looking Statements

#### **Forward-Looking Statements**

This presentation contains certain estimates and forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and may be identified by their use of words like "plans," "expects," "will," "anticipates," "believes," "intends," "projects," "estimates," "outlook," or other words of similar meaning. All statements that address expectations or projections about the future, including statements about Corteva's financial results or outlook; strategy for growth; product development; regulatory approvals; market position; capital allocation strategy; liquidity; environmental, social and governance ("ESG") targets and initiatives; the anticipated benefits of acquisitions, restructuring actions, or cost savings initiatives; and the outcome of contingencies, such as litigation and environmental matters, are forward-looking statements.

Forward-looking statements and other estimates are based on certain assumptions and expectations of future events which may not be accurate or realized. Forward-looking statements and other estimates also involve risks and uncertainties, many of which are beyond Corteva's control. While the list of factors presented below is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on Corteva's business, results of operations and financial condition. Some of the important factors that could cause Corteva's actual results to differ materially from those projected in any such forward-looking statements include: (i) failure to obtain or maintain the necessary regulatory approvals for some of Corteva's products; (ii) failure to successfully develop and commercialize Corteva's pipeline; (iii) effect of the degree of public understanding and acceptance or perceived public acceptance of Corteva's biotechnology and other agricultural products; (iv) effect of changes in agricultural and related policies of governments and international organizations; (v) costs of complying with evolving regulatory requirements and the effect of actual or alleged violations of environmental laws or permit requirements; (vi) effect of climate change and unpredictable seasonal and weather factors; (vii) failure to comply with competition and antitrust laws; (viii) effect of competition in Corteva's industry; (ix) competitor's establishment of an intermediary platform for distribution of Corteva's products; (x) impact of Corteva's dependence on third parties with respect to certain of its raw materials or licenses and commercialization; (xi) effect of volatility in Corteva's input costs; (xii) risks related to environmental litigation and the indemnification obligations of legacy EIDP liabilities in connection with the separation of Corteva; (xiv) risks related to Corteva's global operations; (xv) failure to effectively manage acquisitions, divestitures, alliances, restructurings, cost savings initiatives, and other portfolio actions; (xvi) effect of industrial espionage and other disruptions to Corteva's supply chain, information technology or network systems; (xvii) failure of Corteva's customers to pay their debts to Corteva, including customer financing programs; (xviii) failure to raise capital through the capital markets or short-term borrowings on terms acceptable to Corteva; (xix) increases in pension and other post-employment benefit plan funding obligations; (xx) capital markets sentiment towards ESG matters; (xxi) risks related to pandemics or epidemics; (xxii) Corteva's intellectual property rights or defense against intellectual property claims asserted by others; (xxiii) effect of counterfeit products; (xxiv) Corteva's dependence on intellectual property cross-license agreements; and (xxv) other risks related to the Separation from DowDuPont.

Additionally, there may be other risks and uncertainties that Corteva is unable to currently identify or that Corteva does not currently expect to have a material impact on its business. Where, in any forward-looking statement or other estimate, an expectation or belief as to future results or events is expressed, such expectation or belief is based on the current plans and expectations of Corteva's management and expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the expectation or belief will result or be achieved or accomplished. Corteva disclaims and does not undertake any obligation to update or revise any forward-looking statement, except as required by applicable law. A detailed discussion of some of the significant risks and uncertainties which may cause results and events to differ materially from such forward-looking statements is included in the "Risk Factors" section of Corteva's Annual Report on Form 10-K, as modified by subsequent Quarterly Reports on Forms 10-Q and Current Reports on Form 8-K.



### A Reminder About Non-GAAP Financial Measures

#### Regulation G (Non-GAAP Financial Measures)

This presentation includes information that does not conform to U.S. GAAP and are considered non-GAAP measures. These measures may include organic sales, organic growth (including by segment and region), operating EBITDA, operating EBITDA margin, operating earnings (loss) per share, and base income tax rate. Management uses these measures internally for planning and forecasting, including allocating resources and evaluating incentive compensation. Management believes that these non-GAAP measures best reflect the ongoing performance of the Company during the periods presented and provide more relevant and meaningful information to investors as they provide insight with respect to ongoing operating results of the Company and a more useful comparison of year over year results.

These non-GAAP measures supplement the Company's U.S. GAAP disclosures and should not be viewed as an alternative to U.S. GAAP measures of performance. Furthermore, such non-GAAP measures may not be consistent with similar measures provided or used by other companies. Reconciliations for these non-GAAP measures to U.S. GAAP are provided at the end of this presentation.

Corteva is not able to reconcile its forward-looking non-GAAP financial measures, except for Free Cash Flow, to its most comparable U.S. GAAP financial measures, as it is unable to predict with reasonable certainty items outside of the Company's control, such as Significant Items, without unreasonable effort. For Significant items reported in the periods presented, refer to slide 28. Beginning January 1, 2020, the Company presents accelerated prepaid royalty amortization expense as a significant item. Accelerated prepaid royalty amortization represents the non-cash charge associated with the recognition of upfront payments made to Monsanto in connection with the Company's non-exclusive license in the United States and Canada for Monsanto's Genuity® Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits. During the ramp-up period of Enlist E3<sup>TM</sup>, Corteva has begun to significantly reduce the volume of products with the Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits beginning in 2021, with expected minimal use of the trait platform thereafter. During 2023, the company committed to restructuring activities to optimize the Crop Protection network of manufacturing and external partners, which are expected to be substantially complete in 2024. The company expects to record approximately \$180 million to \$230 million net pre-tax restructuring charges during 2024 for these activities.

Organic sales is defined as price and volume and excludes currency and portfolio and other impacts, including significant items. Operating EBITDA is defined as earnings (loss) (i.e., income (loss) from continuing operations before income taxes) before interest, depreciation, amortization, non-operating benefits (costs), foreign exchange gains (losses), and net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting, excluding the impact of significant items. Non-operating benefits (costs) consists of non-operating pension and other post-employment benefit (OPEB) credits (costs), tax indemnification adjustments, and environmental remediation and legal costs associated with legacy businesses and sites. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the Company as pre-tax income or expense. Operating EBITDA margin is defined as "earnings (loss) per common share from continuing operations - diluted" excluding the after-tax impact of significant items, the after-tax impact of non-operating benefits (costs), the after-tax impact of amortization expense associated with intangible assets existing as of the Separation from DowDuPont, and the after-tax impact of net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting. Although amortization of the Company's intangible assets is excluded from these non-GAAP measures, management believes it is important for investors to understand that such intangible assets have been fully amortized. Any future acquisitions may result in amortization of additional intangible assets. Net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting represents the no

The Company also uses Free Cash Flow and Free Cash Flow Conversion as non-GAAP measures to evaluate and discuss its liquidity position and ability to generate cash. Free Cash Flow is defined as cash provided by (used for) operating activities – continuing operations, less capital expenditures. Free Cash Flow Conversion is defined as Free Cash Flow divided by Operating EBITDA. We believe that Free Cash Flow and Free Cash Flow Conversion provide investors with meaningful information regarding the Company's ongoing ability to generate cash through core operations, and our ability to service our indebtedness, pay dividends (when declared), make share repurchases, and meet our ongoing cash needs for our operations. Corteva is not able to reconcile its forward-looking Free Cash Flow Conversion non-GAAP financial measure to its most comparable U.S. GAAP financial measure, as it is unable to predict with reasonable certainty Operating EBITDA due to items outside of the company's control, which includes the same Significant Items noted above, without reasonable effort.



## **CEO Messages**

# 1H 2024 Financial Performance

- Solid 1H results led by the Seed business and overall operational execution
- Ongoing benefits from controllable levers support margin improvement
- Crop Protection volumes stabilizing although pricing remains competitive

## Overall Ag Market Outlook

- Record-setting demand for grain, oilseeds, and biofuels continues in 2024
- Farmers prioritize top-tier seed technology while managing tighter margins
- Crop Protection impacted by residual destocking and competitive pressures


# Updating FY 2024 Outlook<sup>(2)</sup>


- Net Sales \$17.2 \$17.5B
- Operating EBITDA<sup>(1)</sup> \$3.4B \$3.6B, EBITDA margin ~20% at mid-point
- Increased dividend 6%, ~\$1B in share repurchases expected for FY 2024

# 2024 is Another Year of Growth Driven by Innovation



## **Crop Sector Market Outlook**





#### **Growing Global Demand for Agricultural Commodities**

- Record-setting demand for grain, oilseeds, and meat in 2023/24
- Global demand for biofuels is strong, growth expected again in 2024
- Stocks-to-Use ratios are rebuilding for corn and soybeans

#### **Strong Supply Despite Isolated Disruptions**

- Early wet conditions in the Midwest followed by more favorable weather
- Brazil flooding in Rio Grande do Sul primarily impacting soybean crop
- Impact of corn stunt expected to result in reduced corn area in Argentina

### **Annual Productivity is Key to Farmers' Financial Health**

- Farmers remain focused on investment in top-performing seed technology
- On-farm Crop Protection applications remain steady

# Farmers Drive Productivity by Prioritizing Seed Input Decisions



## **1H 2024 Financial Performance**

Metric	2Q 2024 <sup>(1)</sup>	1H 2024 <sup>(1)</sup>		1H Highlights
Net Sales	<b>\$6.1B ○</b> 1%	<b>\$10.6B ♥</b> 3%	· ·	on declines in EMEA <sup>(3)</sup> and North America
Organic Sales(2)	<b>\$6.2B ○</b> 2%	<b>\$10.7B ○</b> 2%		pased pricing partially offset by volume declines on competitive market and weather challenges
Operating EBITDA <sup>(2)</sup>	<b>\$1.9B 1</b> 0%	<b>\$3.0B ○</b> 1%		/ lower net royalty offset higher commodity costs on productivity offset by cost / currency headwinds
Operating EBITDA Margin <sup>(2)</sup>	<b>31.4% ○</b> 248 bps	<b>27.8%</b> <b>⊙</b> 59 bps	•	expansion on pricing, product mix, and royalties on impacted by destocking / market imbalance


# Seed Momentum Continues, CP Remains Challenged



<sup>(1)</sup> Growth rates versus prior year.

<sup>(2)</sup> Organic sales, Operating EBITDA and Operating EBITDA Margin are non-GAAP measures. See slide 3 for further discussion and reconciliations at the end of this presentation.

## 1H 2024 Sales Highlights



- Seed Growth Driven by Latest Top-Tier Technology Offerings
- CP Revenue Impacted by Competitive Market Pressures



\$3.52B


1H 2024

11%

11%

# 1H 2024 Operating EBITDA<sup>(1)</sup>

#### 1H 2024 Bridge



#### **Key Drivers**

- Broad-based Seed pricing gains across the portfolio to capture value for technology, offsetting Crop Protection competitive pressure
- Volume impacted by Crop Protection destocking and unfavorable weather in EMEA, as well as JIT purchasing in North America
- **~\$110M benefit from Seed net royalties**, driven by Enlist E3<sup>TM(2)</sup>, with both out-licensing income and royalty expense improvements
- Market-driven inflation and other costs offset by ~\$100M in productivity savings for Seed and Crop Protection
- Increase in SG&A versus prior year driven by biologicals
- Currency headwind primarily driven by Turkish Lira, offset in price

# Margin Expansion Against Volume and Currency Headwinds



# **Updated 2024 Guidance**<sup>(1)</sup>

	Prior Guide	Revised Guide	Changes vs Prior Guide
Net Sales	<b>\$17.4 - \$17.7B</b> +2% at mid-point	<b>\$17.2 - \$17.5B</b> +1% at mid-point	<ul> <li>Revenue adjustment primarily reflects updated 2H outlook for Crop Protection</li> </ul>
Operating EBITDA <sup>(2)</sup>	<b>\$3.5 - \$3.7B</b> +6% at mid-point Margin + ~90 bps	<b>\$3.4 - \$3.6B</b> +4% at mid-point Margin + ~55bps	<ul> <li>Impact of lower revenue forecast partially mitigated by cost and productivity actions</li> </ul>
Operating EPS <sup>(2)</sup>	<b>\$2.70 - \$2.90</b> +4% at mid-point	<b>\$2.60 - \$2.80</b> Flat at mid-point	<ul> <li>Lower Operating EBITDA and higher net interest expense, partially offset by lower exchange losses</li> </ul>
Free Cash Flow <sup>(2)</sup>	\$1.5 – \$2.0B	\$1.5 <b>–</b> \$2.0B	<ul> <li>FCF / EBITDA conversion rate 45-50%</li> </ul>

# Outlook for Earnings and Margin Growth



## **2024 1H / 2H Key Drivers**

#### **First Half Performance**

- Strong NA Seed despite reduced corn acres
- Crop Protection competitive pressures
- Modest cost inflation in Crop Protection
- Royalty and productivity benefits
- SG&A down vs 2023, excluding Biologicals

## **Second Half Assumptions**

- Brazil Safrinha area, Argentina corn stunt risk
- Crop Protection volume growth, price pressure
- Crop Protection raw material deflation
- Productivity benefits mirror 1H
- Ongoing cost control

# Volume Growth and Cost Improvements Drive 2H EBITDA



## **Key Takeaways**

1H Results Overall in-line, Updating Full Year 2024 Guidance

Seed Momentum Continues in 2024, driven by Product Performance and Pricing

**Crop Protection Cost Improvement and LATAM Volume drives 2H Outlook** 

1H Cash Flow Performance supports \$1.5 - \$2.0B FCF Full Year 2024 Guidance

## 2024 Updated Guide Reflects Current Market Dynamics





# **Appendix**



## **2Q 2024 Highlights**

(\$ in millions, except EPS)	2Q 2023	2Q 2024	Change
Net Sales	\$6,045	\$6,112	+1%
GAAP Income (Loss) from Continuing Operations After Income Taxes	\$880	\$1,056	+20%
Operating EBITDA <sup>(1)</sup>	\$1,746	\$1,917	+10%
Operating EBITDA Margin <sup>(1)</sup>	28.9%	31.4%	+248 bps
GAAP EPS from Continuing Operations	\$1.23	\$1.51	+23%
Operating EPS <sup>(1)</sup>	\$1.60	\$1.83	+14%









## **2Q 2024 Seed Performance Highlights**

(\$ in millions)	2Q 2024	vPY
Net Sales	\$4,331	+2%
Organic <sup>(1)</sup> Sales Growth		+3%
Operating EBITDA	\$1,698	+16%
Operating EBITDA Margin	39.2%	+501 bps



(3) Other oilseeds includes sunflower and canola.

### 2Q 2024 Revenue by Product Line




#### **Summary Takeaways**

- Broad based price increases, led by North America<sup>(5)</sup>
- Volume declines driven by seasonal delivery timing in North America partially offset by timing in EMEA<sup>(5)</sup>
- Lower royalty expense and ~\$30M of productivity savings offset higher commodity and investment in R&D



## 2Q 2024 Regional Net Sales Highlights – Seed



North America	(2)	Reported 2%	Organic <sup>(1)</sup>
		2Q 2023	2Q 2024
Net Sales (\$	SM)	\$3,696	\$3,753
Volume	Price	Currency	Portfolio
(3)%	5%	- %	- %
Pricing gains driven by strong execution, demand for technology			
Volume decline driven by timing of corn			

EMEA <sup>(2)</sup>	(		Organic <sup>(1)</sup> <b>27%</b>
		2Q 2023	2Q 2024
Net Sales (\$	M)	\$231	\$251
Volume	Price	Currency	Portfolio
19%	8%	(6)%	(12)%

deliveries vs prior year

- Increased volume driven by seasonal timing of deliveries delayed from 1Q into 2Q
- Strong price execution across the portfolio on new technology and to offset currency

Latin America		Reported Flat	Organic <sup>(1)</sup>
		2Q 2023	2Q 2024
Net Sales	(\$M)	\$208	\$207
Volume	Price	Currency	Portfolio
1%	(2)%	1%	- %

Price declines driven by increased competitive pressure in Brazil

Acio

Higher Brazil corn volume offset by declines in Mexico due to drought and expected reduction in Argentina corn area


Pacific		Reported <b>7%</b>	Organic <sup>(1)</sup> 5%
		2Q 2023	2Q 2024
Net Sales (	\$M)	\$129	\$120
Volume	Price	Currency	Portfolio
(15)%	10%	(2)%	- %

- Volume decline due to India corn supply constraints and weather-related delays in Pakistan
- Strong price execution on value of new technology




## **1H 2024 Seed Performance Highlights**

(\$ in millions)	1H 2024	vPY
Net Sales	\$7,082	+2%
Organic <sup>(1)</sup> Sales Growth		+4%
Operating EBITDA	\$2,446	+16%
Operating EBITDA Margin	34.5%	422 bps



(3) Other oilseeds includes sunflower and canola.

#### 1H 2024 Revenue by Product Line




#### **Summary Takeaways**

- Broad based price increases, led by North America<sup>(5)</sup>
- Volume decline driven by lower corn planted area in EMEA
- Lower royalty expense and ~\$45M of productivity savings offset higher commodity and investment in R&D



## 1H 2024 Regional Net Sales Highlights – Seed



North America	(2)	Reported 4%	Organic <sup>(1)</sup>
		1H 2023	1H 2024
Net Sales (\$M)		\$5,019	\$5,224
Volume	Price	Currency	Portfolio
- %	4%	- %	- %

- Pricing gains driven by strong execution, demand for technology
- Volume gains in soybean and cotton offset by exit of alfalfa and lower canola

Reported

Organic<sup>(1)</sup>

EMEA <sup>(2)</sup>	(	6%	<b>0</b> 5%	
		1H 2023	1H 2024	
Net Sales (\$	SM)	\$1,243	\$1,169	
Volume	Price	Currency	Portfolio	
(5)%	10%	(5)%	(6)%	

- Strong price execution across the portfolio on new technology and to offset currency
- Decreased volume driven by reduced corn and sunflower planted area

Latin America		Reported 2%	Organic <sup>(1)</sup>
		1H 2023	1H 2024
Net Sales (	(\$M)	\$467	\$478
Volume	Price	Currency	Portfolio
(3)%	2%	3%	- %

- Volume decline driven by Mexico due to drought and expected reduction in Argentina corn area
- Strong price execution across most of the region offset by competitive pressure in Brazil


Asia Pacific		Reported <b>8%</b>	Organic <sup>(1)</sup> 5%
		1H 2023	1H 2024
Net Sales (\$M)		\$230	\$211
Volume	Price	Currency	Portfolio
(14)%	9%	(3)%	- %

- Volume decline due to decrease in Pakistan corn planted area
- Strong price execution on value of new technology




## 2Q 2024 Crop Protection Performance Highlights

(\$ in millions)	2Q 2024	vPY
Net Sales	\$1,781	- %
Organic <sup>(1)</sup> Sales Growth		+1%
Operating EBITDA	\$255	(20)%
Operating EBITDA Margin	14.3%	(365) bps



### 2Q 2024 Revenue by Product Line



#### **Summary Takeaways**

- Pricing declines in all regions, driven by competitive pressure and market imbalance
- Volume gains led by Latin America and North America, demand for new products and spinosyns
- LSD raw material cost inflation, partially offset by ~\$20M of productivity savings



<sup>(1)</sup> Organic sales growth is a non-GAAP measure. See slide 3 for further discussion and reconciliations at the end of this presentation.

<sup>(2)</sup> Cost is net of productivity actions.

<sup>(3)</sup> Other product line primarily includes seed applied technology and biologicals.

## 2Q 2024 Regional Net Sales Highlights – Crop Protection



North America	(2)	Reported 4%	Organic <sup>(1)</sup> 4%
		2Q 2023	2Q 2024
Net Sales (\$	SM)	\$623	\$647
Volume	Price	Currency	Portfolio
9%	(5)%	- %	- %

- Higher volumes driven by shift in timing of demand until closer to application window
- Price declines driven by increased competitive pressure

EMEA <sup>(2)</sup>		Reported 13%	Organic <sup>(1)</sup>	
		2Q 2023	2Q 2024	
Net Sales (S	Net Sales (\$M)		\$422	
Volume	Price	Currency	Portfolio	
(11)%	(1)%	(1)%	- %	
Lower volumes driven by residual				

- Lower volumes driven by residual destocking and unfavorable weather
- Price declines driven by increased competitive pressure

_	America		11% Organic	
			2Q 2023	2Q 2024
	Net Sales (\$M)		\$400	\$443
	Volume	Price	Currency	Portfolio
Ī	21%	(10)%	- %	- %

Latin

- Volume gains driven by demand for new products and spinosyns
- Price declines driven by increased competitive pressure


Asia Pacific		Reported 2%	Organic <sup>(1)</sup> 1%
		2Q 2023	2Q 2024
Net Sales (S	\$M)	\$275	\$269
Volume	Price	Currency	Portfolio
5%	(4)%	(3)%	- %

- Volume gains driven by demand for new products and spinosyns
- Price declines driven by increased competitive pressure




## 1H 2024 Crop Protection Performance Highlights

(\$ in millions)	1H 2024	vPY
Net Sales	\$3,522	(11)%
Organic <sup>(1)</sup> Sales Growth		(11)%
Operating EBITDA	\$565	(39)%
Operating EBITDA Margin	16.0%	(721) bps



#### 1H 2024 Revenue by Product Line



### **Summary Takeaways**

- Pricing gains in EMEA<sup>(4)</sup> offset by declines in North America<sup>(4)</sup>
   and Latin America, driven by competitive pressure
- Volume declines driven by strong prior year comparison, justin-time purchasing behavior and weather in EMEA<sup>(4)</sup>
- LSD raw material cost inflation, partially offset by ~\$55M of productivity savings




<sup>)</sup> Organic sales growth is a non-GAAP measure. See slide 3 for further discussion and reconciliations at the end of this presentation.

<sup>(2)</sup> Cost is net of productivity actions.

<sup>(3)</sup> Other product line primarily includes seed applied technology and biologicals.

<sup>(4)</sup> North America is defined as U.S. and Canada. EMEA is defined as Europe, Middle East and Africa.

## 1H 2024 Regional Net Sales Highlights – Crop Protection



North America <sup>(2)</sup>		Reported 16%	Organic <sup>(1)</sup> <b>16%</b>
		1H 2023	1H 2024
Net Sales (S	SM)	\$1,502	\$1,263
Volume	Price	Currency	Portfolio
(11)%	(5)%	- %	- %

- Lower volumes driven by just-in-time purchasing behavior
- Price declines driven by increased competitive pressure

 $EMEA^{(2)}$ 

	V 10 /0	10 /0
	1H 2023	1H 2024
Net Sales (\$M)	\$1,284	\$1,092

Reported

**15%** 

Organic<sup>(1)</sup>

**0**13%

Volume	Price	Currency	Portfolio
(15)%	2%	(3)%	1%

- Lower volumes driven unfavorable weather and lower planted area impacting spring applications
- Pricing gains to largely offset currency impact

Latin America			Organic <sup>(1)</sup> <b>5%</b>
		1H 2023	1H 2024
Net Sales (\$M)		\$693	\$687
Volume	Price	Currency	Portfolio
6%	(11)%	1%	3%

- Price declines driven by increased competitive pressure
- Volume gains driven by demand for new products, spinosyns, and biologicals

Asia Pacific		Reported 2%	Organic <sup>(1)</sup> 1%
		1H 2023	1H 2024
Net Sales (\$M)		\$491	\$480
Volume	Price	Currency	Portfolio
4%	(3)%	(3)%	- %

- Volume gains driven by demand for new products and spinosyns
- Price declines driven by increased competitive pressure




# **2Q 2024 Operating EPS**<sup>(1)</sup> Variance





# FY 2024 Operating EBITDA<sup>(1)</sup>






#### **Key Drivers**

- **LSD pricing gains in Seed** to capture value for technology, offset by elevated pricing pressure in Crop Protection
- Volume gains in both Seed and Crop Protection, led by Latin America, driven by increased 2024 / 2025 Safrinha area and Crop Protection market stabilization
- ~\$130M improvement in Seed net royalties, driven by Enlist E3<sup>TM(2)</sup>, on both out-licensing income and royalty expense
- ~\$300M Cost benefits from productivity, Crop Protection input cost deflation, and other cost actions
- **R&D** and **SG&A** spend increase driven by pipeline investment, normalized bad debt, and compensation accruals

## Margin Expansion on Higher Volume and Controllable Levers



## Enlist E3<sup>TM(1)</sup>: Impressive Growth Trajectory throughout the Cycle



- Enlist E3<sup>™</sup> remains number one selling soybean technology in the U.S.
- Enlist E3<sup>TM</sup> >80% of Corteva U.S. soybean lineup in 2024 and on track for >90% in 2025
- Enlist system 2024 sales expected ~\$1.8B
- Enlist herbicide expected spray rate ~75%
- Primary driver of ~\$450M improvement in net royalty
   expense expected in 2024 versus 2020
- Launched Z-series soybeans in 2024, driving more yield and value at the farm

# Enlist E3<sup>TM</sup> Soybeans Expected Market Penetration >65% in 2024



# FY 2024 Modeling Guidance – Operating Earnings Per Share<sup>(1)</sup>

(\$ in millions, except where noted)	Guidance					
Depreciation and Post-Merge Amortization	(610 - 620)					
Net Interest (Expense) Income	(125 – 135)					
Base Income Tax Rate <sup>(1)</sup>	21% - 23%					
Exchange Losses – net, after tax	(250 - 270)					
Net Income – Non-controlling interest	(12)					
Diluted Shares	697 – 700					
Operating Earnings Per Share <sup>(1)</sup>	\$2.60 – 2.80					

(\$ in millions, except where noted)	Cash Flow Guidance
Amortization	~\$630
Capital Expenditures	~\$630



Corteva, Inc.
Non-GAAP Calculation of Corteva Operating EBITDA

			Three Months I	Ended Jur	ne 30,		Six Months Ended June 30,			
		202	24		20	23	20	24	2023	
In millions	As R	eported	Margin %	As Repo	orted	Margin %	As Reported	Margin %	As Reported	Margin %
Income (loss) from continuing operations after income taxes (GAAP)	\$	1,056	17.3%	\$	880	14.6%	\$ 1,432	13.5%	\$ 1,487	13.6%
Provision for (benefit from) income taxes on continuing operations		282	4.6%		204	3.4%	388	3.7%	373	3.4%
Income (loss) from continuing operations before income taxes (GAAP)	\$	1,338	21.9%	\$	1,084	17.9%	\$ 1,820	17.2%	\$ 1,860	17.0%
+ Depreciation and Amortization		312	5.1%		306	5.1%	619	5.8%	593	5.4%
- Interest income		(25)	-0.4%		(54)	-0.9%	(60)	-0.6%	(94)	-0.9%
+ Interest expense		66	1.1%		82	1.4%	107	1.0%	113	1.0%
+ / - Exchange (gains) losses		78	1.3%		104	1.7%	137	1.3%	140	1.3%
+ / - Non-operating (benefits) costs		30	0.5%		44	0.7%	82	0.8%	87	0.8%
+ / - Mark-to-market (gains) losses on certain foreign currency contracts not designated as hedge		(19)	-0.3%		63	1.0%	(18)	-0.2%	78	0.7%
+ / - Significant items (benefit) charge		137	2.2%		117	1.9%	264	2.5%	200	1.8%
Corteva Operating EBITDA / EBITDA Margin (Non-GAAP) 1,2	\$	1,917	31.4%	\$	1,746	28.9%	\$ 2,951	27.8%	\$ 2,977	27.2%

<sup>1.</sup> Corteva Operating EBITDA is defined as earnings (loss) (i.e., income (loss) from continuing operations before income taxes) before interest, depreciation, amortization, non-operating benefits (costs), foreign exchange gains (losses), and net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting, excluding the impact of significant items. Non-operating benefits (costs) consists of non-operating pension and other post-employment benefit (OPEB) credits (costs), tax indemnification adjustments, and environmental remediation and legal costs associated with legacy businesses and sites. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the company as pre-tax income or expense.



<sup>2.</sup> The EBITDA margin percentages are determined by dividing amounts in the table above for the three months ended June 30, 2024 and 2023 by net sales of \$6,112 million and \$6,045 million, respectively, and amounts for the six months ended June 30, 2024 and 2023 by net sales of \$10,604 million and \$10,929 million, respectively. Margin percentages may not foot, due to rounding.

#### Corteva, Inc. Segment Information

Net sales by segment

						ix Months E	Ended June 30,		
In millions	202	4	202	23	202	24		2023	
Seed	\$	4,331	\$	4,264	\$	7,082	\$	6,959	
Crop Protection		1,781		1,781		3,522		3,970	
Total net sales	\$	6,112	\$	6,045	\$	10,604	\$	10,929	

#### Net Margin (GAAP)

	Three Months	Ended June 30,	Six Months E	nded June 30,
\$ In millions	2024	2023	2024	2023
Income (loss) from continuing operations after income taxes	\$ 1,056	\$ 880	\$ 1,432	\$ 1,487
Net Margin (GAAP) <sup>1</sup>	17.3%	14.6%	13.5%	13.6%

<sup>1.</sup> Net Margin is defined as income (loss) from continuing operations after income taxes, as a percentage of net sales.

#### Corteva Operating EBITDA

	Three Months	Ended June 30,	Ended June 30,		
In millions	2024	2023	2024	2023	
Seed	\$ 1,698	\$ 1,458	\$ 2,446	\$ 2,110	
Crop Protection	255	320	565	923	
Corporate Expenses	(36	(32)	(60)	(56)	
Corteva Operating EBITDA (Non-GAAP) <sup>2</sup>	\$ 1,917	\$ 1,746	\$ 2,951	\$ 2,977	

<sup>2.</sup> Corteva Operating EBITDA is defined as earnings (loss) (i.e., income (loss) from continuing operations before income taxes) before interest, depreciation, amortization, non-operating benefits (costs), foreign exchange gains (losses), and net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting, excluding the impact of significant items. Non-operating benefits (costs) consists of non-operating pension and OPEB credits (costs), tax indemnification adjustments, and environmental remediation and legal costs associated with legacy businesses and sites. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the company as pre-tax income or expense.

#### Operating EBITDA margin

	Three Months Ended June 30, Six Months Ended June 3				
	2024	2023	2024	2023	
Seed	39.2%	34.2%	34.5%	30.3%	
Crop Protection	14.3%	18.0%	16.0%	23.2%	
Total Operating EBITDA margin (Non-GAAP) 3,4	31.4%	28.9%	27.8%	27.2%	

<sup>3.</sup> Operating EBITDA margin is Operating EBITDA as a percentage of net sales.

<sup>4.</sup> Operating EBITDA margin %'s for Corporate are not presented separately above as they are not meaningful; however, the results are included in the Total margin %'s above.



	Corteva si	gnificant items	(Pretax)
--	------------	-----------------	----------

	Three Months	End	ded June 30,	Six Months E	nded June 30,
In millions	2024		2023	2024	2023
Seed					
Restructuring and asset-related charges - net	\$ (33)	\$	(54)	\$ (53)	\$ (75)
Inventory write-offs	2		(3)	2	(7)
Gain (loss) on sale of assets	-		-	4	-
Seed sale associated with Russia Exit	-		(1)	<u>-</u>	18
Total Seed	\$ (31)	\$	(58)	\$ (47)	\$ (64)
Crop Protection					
Restructuring and asset-related charges - net	\$ (32)	\$	(5)	\$ (73)	\$ (11)
Estimated settlement expense	(47)		(41)	(101)	(90)
Gain (loss) on sale of business, assets and equity investments	3		-	3	3
Acquisition-related costs	(3)		(15)	(5)	(34)
Employee Retention Credit	-		3	<del>-</del>	3
Total Crop Protection	\$ (79)	\$	(58)	\$ (176)	\$ (129)
Corporate					
Restructuring and asset-related charges - net	\$ (27)	\$	(1)	\$ (41)	\$ (7)
Total Corporate	\$ (27)	\$	(1)	\$ (41)	\$ (7)
Total significant items by segment (Pretax)	\$ (137)	\$	(117)	\$ (264)	\$ (200)
Total tax impact of significant items <sup>1</sup>	34		27	66	42
Tax only significant items	-		29	-	29
Total significant items charge, net of tax <sup>2</sup>	\$ (103)	\$		\$ (198)	

<sup>1.</sup> Unless specifically addressed above, the income tax effect on significant items was calculated based upon the enacted tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment.



<sup>2.</sup> Refer to page A-10 of the Financial Statement Schedules for further information on significant items, including tax only items.

Corteva, Inc. Segment Information - Price, Volume Currency Analysis

Region

		Q2 2024 v	s. Q2 2023		Percent Change Due To:					
	Net Sales 0	hange (GAAP)	Organic Chang	je (Non-GAAP) <sup>2</sup>						
	\$ (millions)	%	\$ (millions)	%	Price & Product Mix	Volume	Currency	Portfolio / Other		
North America <sup>1</sup>	\$ 8	2%	\$ 83	2%	3%	(1)%	-%	-%		
EMEA <sup>1, 3</sup>	(41	(6)%	7	1%	2%	(1)%	(3)%	(4)%		
Latin America	42	7%	41	7%	(7)%	14%	-%	-%		
Asia Pacific	(15	(4)%	(4)	(1)%	1%	(2)%	(3)%	-%		
Rest of World	(14	(1)%	44	3%	(1)%	4%	(2)%	(2)%		
Total	\$ 67	1%	\$ 127	2%	2%	-%	-%	(1)%		

#### Seed

			Q2 2024 v	s. Q2 2023		Percent Change Due To:					
	Net Sales Change (GAAP)			Organic Chan	ge (Non-GAAP)²						
		\$ (millions)	%	\$ (millions)	%	Price & Product Mix	Volume	Currency	Portfolio / Other		
North America <sup>1</sup>	\$	57	2%	\$ 58	2%	5%	(3)%	-%	-%		
EMEA <sup>1, 3</sup>		20	9%	63	27%	8%	19%	(6)%	(12)%		
Latin America		(1)	-%	(3	(1)%	(2)%	1%	1%	-%		
Asia Pacific		(9)	(7)%	(7	(5)%	10%	(15)%	(2)%	-%		
Rest of World		10	2%	53	9%	5%	4%	(2)%	(5)%		
Total	\$	67	2%	\$ 111	3%	5%	(2)%	-%	(1)%		

#### **Crop Protection**

		Q2 2024 v	/s. Q	2 2023		Percent Change Due To:					
	Net Sales Change (GAAP)			Organic Chang	e (Non-GAAP) <sup>2</sup>						
	\$ (millions)	%		\$ (millions)	%	Price & Product Mix	Volume	Currency	Portfolio / Other		
North America <sup>1</sup>	\$ 24	4%	6 \$	25	4%	(5)%	9%	-%	-%		
EMEA <sup>1</sup>	(61)	(13)%	ó	(56)	(12)%	(1)%	(11)%	(1)%	-%		
Latin America	43	11%	ó	44	11%	(10)%	21%	-%	-%		
Asia Pacific	(6)	(2)%	ó	3	1%	(4)%	5%	(3)%	-%		
Rest of World	(24)	(2)%	ó	(9)	(1)%	(5)%	4%	(1)%	-%		
Total	\$ -	-%	ó \$	16	1%	(5)%	6%	(1)%	-%		



#### Seed Product Line

	_											
			Q2 2024 v	s. Q2 2023			Percent Change Due To:					
		Net Sales Change (GAAP)		Organic C	Organic Change (Non-GAAP) <sup>2</sup>							
		\$ (millions) %		\$ (millions)		%	Price & Product Mix	Volume	Currency	Portfolio / Other		
Corn <sup>3</sup>	\$	10	-%	\$	41	2%	5%	(3)%	(1)%	(1)%		
Soybeans		62	5%		62	5%	4%	1%	-%	-%		
Other oilseeds <sup>3</sup>		(8)	(4)%		4	2%	2%	-%	(1)%	(5)%		
Other		3	2%		4	3%	12%	(9)%	(1)%	-%		
Total	\$	67	2%	\$	111	3%	5%	(2)%	-%	(1)%		

#### **Crop Protection Product Line**

			Q2 2024 v	s. Q2 2023				Percent Cha	nge Due To:	
		Net Sales Ch	Organic	Organic Change (Non-GAAP) <sup>2</sup>						
	,	\$ (millions)	%	\$ (millions)	)	%	Price & Product Mix	Volume	Currency	Portfolio / Other
Herbicides	\$	(40)	(4)%	\$	(34)	(3)%	(5)%	2%	(1)%	-%
Insecticides		84	25%		87	26%	(4)%	30%	(1)%	-%
Fungicides		(2)	(1)%		1	-%	(9)%	9%	(1)%	-%
Other		(42)	(20)%		(38)	(18)%	-%	(18)%	(2)%	-%
Total	\$	-	-%	\$	16	1%	(5)%	6%	(1)%	-%



Danian
Region

		First Half 2024 v	s. First Half 2023		Percent Change Due To:						
	Net Sales Change (GAAP)		Organic Chang	ge (Non-GAAP) <sup>2</sup>							
	\$ (millions)	%	\$ (millions)	%	Price & Product Mix	Volume	Currency	Portfolio / Other			
North America <sup>1</sup>	\$ (34)	(1)%	\$ (36)	(1)%	2%	(3)%	-%	-%			
EMEA <sup>1, 3</sup>	(266)	(11)%	(96)	(4)%	6%	(10)%	(4)%	(3)%			
Latin America	5	-%	(40)	(3)%	(5)%	2%	2%	1%			
Asia Pacific	(30)	(4)%	(9)	(1)%	1%	(2)%	(3)%	-%			
Rest of World	(291)	(7)%	(145)	(3)%	2%	(5)%	(3)%	(1)%			
Total	\$ (325)	(3)%	\$ (181)	(2)%	2%	(4)%	(1)%	-%			

#### Seed

		First Half 2024 v	/s. Firs	st Half 2023		Percent Change Due To:						
	Net Sales Change (GAAP)			Organic Chang	e (Non-GAAP) <sup>2</sup>							
	\$ (millions)	%		\$ (millions)	%	Price & Product Mix	Volume	Currency	Portfolio / Other			
North America <sup>1</sup>	\$ 205	4%	\$	205	4%	4%	-%	-%	-%			
EMEA <sup>1, 3</sup>	(74)	(6)%	5	65	5%	10%	(5)%	(5)%	(6)%			
Latin America	11	2%	5	(5)	(1)%	2%	(3)%	3%	-%			
Asia Pacific	(19)	(8)%	ò	(12)	(5)%	9%	(14)%	(3)%	-%			
Rest of World	(82)	(4)%	,	48	3%	8%	(5)%	(3)%	(4)%			
Total	\$ 123	2%	\$	253	4%	5%	(1)%	(1)%	(1)%			

#### **Crop Protection**

		First Half 2024 v	s. First Half 2023		Percent Change Due To:						
	Net Sales Change (GAAP)		Organic Chang	e (Non-GAAP) <sup>2</sup>							
	\$ (millions)	%	\$ (millions)	%	Price & Product Mix	Volume	Currency	Portfolio / Other			
North America <sup>1</sup>	\$ (239)	(16)%	\$ (241)	(16)%	(5)%	(11)%	-%	-%			
EMEA <sup>1</sup>	(192)	(15)%	(161)	(13)%	2%	(15)%	(3)%	1%			
Latin America	(6)	(1)%	(35)	(5)%	(11)%	6%	1%	3%			
Asia Pacific	(11)	(2)%	3	1%	(3)%	4%	(3)%	-%			
Rest of World	(209)	(8)%	(193)	(7)%	(2)%	(5)%	(2)%	1%			
Total	\$ (448)	(11)%	\$ (434)	(11)%	(4)%	(7)%	(1)%	1%			



#### Seed Product Line

		First Half 2024 v	s. First	Half 2023		Percent Change Due To:					
	Net Sales Change (GAAP)			Organic Chang	e (Non-GAAP) <sup>2</sup>						
	\$ (millions)	%	\$	S (millions)	%	Price & Product Mix	Volume	Currency	Portfolio / Other		
Corn <sup>3</sup>	\$ 118	3%	\$	190	4%	6%	(2)%	(1)%	-%		
Soybeans	85	6%		85	6%	4%	2%	-%	-%		
Other oilseeds <sup>3</sup>	(64)	(13)%		(5)	(1)%	7%	(8)%	(5)%	(7)%		
Other	(16)	(6)%		(17)	(6)%	5%	(11)%	-%	-%		
Total	\$ 123	2%	\$	253	4%	5%	(1)%	(1)%	(1)%		

#### **Crop Protection Product Line**

		First Half 2024 v	s. Firs	st Half 2023		Percent Change Due To:					
	Net Sales Change (GAAP)			Organic Chang	e (Non-GAAP) <sup>2</sup>						
	\$ (millions)	%		\$ (millions)	%	Price & Product Mix	Volume	Currency	Portfolio / Other		
Herbicides	\$ (396)	(18)%	\$	(389)	(17)%	(4)%	(13)%	(1)%	-%		
Insecticides	48	6%		71	10%	(1)%	11%	(4)%	-%		
Fungicides	(66)	(11)%		(56)	(9)%	(4)%	(5)%	(2)%	-%		
Other	(34)	(9)%	)	(60)	(15)%	(2)%	(13)%	(2)%	8%		
Total	\$ (448)	(11)%	\$	(434)	(11)%	(4)%	(7)%	(1)%	1%		

<sup>1.</sup> North America is defined as U.S. and Canada. EMEA is defined as Europe, Middle East and Africa.



<sup>2.</sup> Organic sales is defined as price and volume and excludes currency and portfolio impacts and other impacts, including significant items.

<sup>3.</sup> Other during the three and six months ended June 30, 2023 includes the revenue recognized relating to seed sales associated with the Russia Exit. Refer to page A-10 of the Financial Statement Schedules for further detail on significant items.

#### Corteva, Inc.

#### Non-GAAP Calculation of Corteva Operating EPS

		Three Months	Ended June 30,	
	2024	2023	2024	2023
	\$ (millions)	\$ (millions)	EPS (diluted)	EPS (diluted)
Income (loss) from continuing operations attributable to Corteva (GAAP)	\$ 1,053	\$ 877	\$ 1.51	\$ 1.23
Less: Non-operating benefits (costs), after tax <sup>1</sup>	(21)	(35)	(0.03)	(0.04)
Less: Amortization of intangibles (existing as of Separation), after tax	(118)	(118)	(0.16)	(0.17)
Less: Mark-to-market gains (losses) on certain foreign currency contracts not designated as hedges,	15	(48)	0.02	(0.07)
Less: Significant items benefit (charge), after tax	(103)	(61)	(0.15)	(0.09)
Operating Earnings (Loss) (Non-GAAP) <sup>2</sup>	\$ 1,280	\$ 1,139	\$ 1.83	\$ 1.60

		Six Months E	nde	d June 30,	
	2024	2023		2024	2023
	\$ (millions)	\$ (millions)	Е	EPS (diluted)	EPS (diluted)
Income (loss) from continuing operations attributable to Corteva (GAAP)	\$ 1,425	\$ 1,480	\$	2.03	\$ 2.07
Less: Non-operating benefits (costs), after tax <sup>1</sup>	(61)	(68)	\$	(0.09)	(0.10)
Less: Amortization of intangibles (existing as of Separation), after tax	(235)	(236)	\$	(0.34)	(0.33)
Less: Mark-to-market gains (losses) on certain foreign currency contracts not designated as hedges,	14	(59)	\$	0.02	(0.08)
Less: Significant items benefit (charge), after tax	(198)	(129)	\$	(0.28)	(0.18)
Operating Earnings (Loss) (Non-GAAP) <sup>2</sup>	\$ 1,905	\$ 1,972	\$	2.72	\$ 2.76

<sup>1.</sup> Non-operating benefits (costs) consists of non-operating pension and other post-employment benefit (OPEB) credits (costs), tax indemnification adjustments, and environmental remediation and legal costs associated with legacy businesses and sites. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the Company as pre-tax income or expense.



<sup>2.</sup> Operating earnings (loss) is defined as income (loss) from continuing operations attributable to Corteva excluding the after-tax impact of significant items, the after-tax impact of non-operating benefits (costs), the after-tax impact of amortization of intangible assets existing as of the Separation from DowDuPont, and the after-tax impact of net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting. Although amortization of the company's intangible assets is excluded from these non-GAAP measures, management believes it is important for investors to understand that such intangible assets contribute to revenue generation. Amortization of intangible assets that relate to past acquisitions will recur in future periods until such intangible assets have been fully amortized. Any future acquisitions may result in amortization of additional intangible assets. Net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting represents the non-cash net gain (loss) from charges in fair value of certain undesignated foreign currency derivative contracts. Upon settlement, which is within the same calendar year of execution of the contract, the realized gain (loss) from the changes in fair value of the non-qualified foreign currency derivative contracts will be reported in the relevant non-GAAP financial measures, allowing quarterly results to reflect the economic effects of the foreign currency derivative contracts without the resulting unrealized mark to fair value volatility.

#### Corteva, Inc.

#### Non-GAAP Calculation of Corteva Base Tax Rate

	Three Months Ended June 30,				Six Months E	nded June 30,
		2024	2023		2024	2023
Income (loss) from continuing operations before income taxes (GAAP)	\$	1,338	\$ 1,08	4 \$	1,820	\$ 1,860
Add: Significant items (benefit) charge		137	11	7	264	200
Non-operating (benefits) costs		30	4	1	82	87
Amortization of intangibles (existing as of Separation)		154	15	5	308	309
Mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges		(19)	6	3	(18)	78
Less: Exchange gains (losses) <sup>2</sup>		(78)	(10	1)	(137)	(140)
Income (loss) from continuing operations before income taxes, significant items, non-operating						
(benefits) costs, amortization of intangibles (existing as of Separation), mark-to-market (gains) losses on						
certain foreign currency contracts not designated as hedges, and exchange gains (losses) (Non-GAAP)	\$	1,718	\$ 1,56	7 \$	2,593	\$ 2,674
Provision for (benefit from) income taxes on continuing operations (GAAP)	\$	282	\$ 20	4 \$	388	\$ 373
Add: Tax benefits on significant items (benefit) charge		34	5	3	66	71
Tax expenses on non-operating (benefits) costs		9		9	21	19
Tax benefits on amortization of intangibles (existing as of Separation)		36	3	7	73	73
Tax benefits on mark-to-market (gains) losses on certain foreign currency contracts not designated as hedge		(4)	1	5	(4)	19
Tax benefits on exchange gains (losses) <sup>2</sup>		30	1	3	37	24
Provision for (benefit from) income taxes on continuing operations before significant items, non-						
operating (benefits) costs, amortization of intangibles (existing as of Separation), mark-to-market (gains)						
losses on certain foreign currency contracts not designated as hedges, and exchange gains (losses)	\$	387	\$ 33	1 \$	581	\$ 579
Effective income tax rate (GAAP)		21.1%	18.8	%	21.3%	20.1%
Significant items, non-operating (benefits) costs, amortization of intangibles (existing as of Separation), and mark-						
to-market (gains) losses on certain foreign currency contracts not designated as hedges effect		0.7%	3.0	%	0.9%	1.8%
Tax rate from continuing operations before significant items, non-operating (benefits) costs, amortization of						
intangibles (existing as of Separation), and mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges		21.8%	21.9	%	22.2%	21.8%
Exchange gains (losses), net effect <sup>2</sup>		0.7%	(0.5)		0.2%	
Base income tax rate from continuing operations (Non-GAAP) <sup>1</sup>		22.5%	21.3	_	22.4%	, ,

<sup>1.</sup> Base income tax rate is defined as the effective tax rate excluding the impacts of foreign exchange gains (losses), non-operating benefits (costs), amortization of intangibles (existing as of the Separation), mark-to-market gains (losses) on certain foreign currency contracts not designated as hedges, and significant items.

<sup>2.</sup> Refer to page A-15 of the Financial Statement Schedules for further information on exchange gains (losses).



#### Corteva, Inc.

Non-GAAP Calculation of Free Cash Flow

	Twelve	Months Ended
In millions	Dece	mber 31, 2023
Cash provided by (used for) operating activities - continuing operations (GAAP)	\$	1,809
Less: Capital expenditures		(595)
Free Cash Flow (Non-GAAP) <sup>1</sup>	\$	1,214

	Twelve Months Ended December 31, 2024 <sup>2</sup>			
In millions	Lov	v End		High End
Cash provided by (used for) operating activities - continuing operations (GAAP	\$	2,130	\$	2,630
Less: Capital expenditures		(630)		(630)
Free Cash Flow (Non-GAAP) <sup>1</sup>	\$	1,500	\$	2,000

<sup>1.</sup> Free cash flow is defined as cash provided by (used for) operating activities - continuing operations, less capital expenditures.



<sup>2.</sup> This represents the reconciliation of the Company's range provided for its forward-looking non-GAAP financial measure relating to Free Cash Flow.

Adavelt" active

Arylex" active

Inatreq" active

















Pyraxalt\* active

Rinskor" active

**Reklemel**<sup>™</sup> active

**Zorvec**<sup>™</sup> active





















#### **Product Disclosures**

TM ® SM Trademarks and service marks of Corteva Agriscience and its affiliated companies. © 2024 Corteva and its affiliated companies.

The transgenic soybean event in Enlist E3® soybeans is jointly developed and owned by Corteva Agriscience LLC and M.S. Technologies, L.L.C. Enlist Duo® and Enlist One® herbicides are not registered for sale or use in all states or counties. Contact your state pesticide regulatory agency to determine if a product is registered for sale or use in your area. Enlist Duo and Enlist One are the only 2,4-D products authorized for use with Enlist crops. Consult Enlist herbicide labels for weed species controlled. Always read and follow label directions.

Qrome® products are approved for cultivation in the U.S. and Canada. They have also received approval in a number of importing countries, most recently China. For additional information about the status of regulatory authorizations, visit http://www.biotradestatus.com/

Pioneer® brand products are provided subject to the terms and conditions of purchase which are part of the labeling and purchase document.

